ment and without edema ( Figure 1 ). On T 2 -weighted images, these lesions showed high signal intensity. Amphotericin B (2 mg/kg daily) was initiated for presumed CNS fungal infecCentral nervous system (CNS) aspergillosis carries a uniformly poor prognosis in bone marrow transplant recipition, and corticosteroids were tapered. Culture of a stereotactic brain biopsy specimen revealed Aspergillus fumigatus. ents. Amphotericin B can be bound to lipid carriers leading to improvement of its therapeutic index. We describe Progressive flaccid quadriparesis, expressive aphasia and absence seizures developed 10 days after starting amphothe successful medical management of CNS aspergillosis in an allogeneic bone marrow transplant patient with tericin B (cumulative dose 840 mg). Repeat MRI showed extensive spread of the lesions throughout both cerebral and administration of Amphotericin B Lipid Complex.
Aspergillosis involving the central nervous system (CNS) is a rare complication of bone marrow transplantation without reported survivors despite combined conventional antifungal therapy and surgery. Amphotericin B Lipid Complex (ABLC; The Liposome Company, Princeton, NJ, USA) is a lipid-associated formulation of amphotericin B that permits delivery of higher dosages, resulting in an increased therapeutic index. 1 We report successful treatment of CNS aspergillosis in a marrow transplant recipient.
Case report
A 14-year-old girl with Philadelphia chromosome-positive ALL failed conventional induction chemotherapy and underwent blood stem cell transplantation from her partially (5/6) HLA-matched brother. Neutrophil engraftment occurred on day +10. Grade II acute graft-versus-host disease (GVHD) of the skin and liver was treated successfully with corticosteroids and antithymocyte globulin. Gancyclovir was given for CMV infection.
On day +76, the patient developed altered mental status, proximal weakness and tonic-clonic seizures. MRI revealed low-signal lesions on T 1 -weighted images in the right frontoparietal lobe and cerebellum with minimal marginal enhance- tologic changes of hepatic GVHD were not present. ABLC was discontinued and amphotericin B re-started, and cholestasis resolved. The cumulative dose of ABLC was 29 775 mg. The patient was discharged to a rehabilitation center and subsequently home 9 months after the diagnosis of CNS aspergillosis. Two months later, the patient died from Parainfluenza interstitial pneumonitis. There was no clinical evidence of CNS aspergillosis. No autopsy was performed.
Discussion
Invasive aspergillosis is a serious problem in patients receiving bone marrow transplants, with a fatality rate approaching 100%. 2 Prolonged neutropenia and GVHD and its treatment are risk factors. An aggressive neurosurgical approach along with itraconazole and liposomal amphotericin B cured a 2-year-old ALL patient who developed CNS aspergillosis while receiving conventional chemotherapy.
3 To our knowledge, our report describes the only survivor of CNS aspergillosis in a transplant recipient. Although amphotericin B may have contributed to the positive outcome in this patient, worsening neurologic symptoms occurring 10 days after starting the antifungal drug, along with progression of radiographic abnormalities in the brain suggested failure to respond to this agent. Subsequent neurologic improvement was observed after initiation of ABLC. dependent cholestasis observed with ABLC is thought to be related to the phospholipid vehicle. The liver biopsy revealed pathologic features that resemble the total parenteral nutrition (TPN)-associated cholestasis syndrome described with prolonged administration of lipid-containing TPN formulations: biliary stasis, portal inflammation, and bile duct proliferation. 
